Physiomics Regulatory News (PYC)

12 December 2024

Physiomics plc

("Physiomics" or the "Company")

Contract Award

Physiomics plc (AIM: PYC), a leading mathematical modelling, data science and biostatistics company supporting the development of new therapeutics and personalised medicine solutions, is pleased to announce a new contract with its long-standing client, Numab Therapeutics AG.

The project will involve the application of Pharmacokinetic-Pharmacodynamic (PK/PD) modelling to inform the Target Candidate Profile ("TCP") of a key asset in Numab Therapeutic's pipeline. Delivery of the project is expected to complete within the next 6 months.

This latest collaboration builds on Physiomics' strong relationship with Numab Therapeutics AG and highlights its expertise in using modelling and simulation approaches to accelerate the development of innovative therapies across a range of therapeutic areas and across the entire drug development pathway, including early discovery and development.

Dr Peter Sargent, CEO of Physiomics, commented:

"We are excited to build on our partnership with Numab Therapeutics AG and contribute to the advancement of this innovative therapy. This collaboration highlights our growing ability to provide comprehensive support to our clients, addressing critical challenges and adding value at multiple stages of the drug development process."

For more information about Physiomics and its services, please visit www.physiomics.co.uk.

Enquiries:

Physiomics plc

Dr Peter Sargent, CEO

+44 (0)1235 841575

Hybridan LLP (Broker)

Claire Louise Noyce

+44 (0) 203 764 2341

Strand Hanson Ltd (NOMAD)

James Dance & James Bellman

+44 (0)20 7409 3494

Notes to Editor

About Physiomics

Physiomics plc combines expertise across Modelling & Simulation, Biostatistics, Data Science and Bioinformatics, together with deep biology expertise, to help biotech and pharma companies streamline their drug development journeys. Our approach is to help derive insight from all relevant and often disparate data in order to de-risk decision making and optimise research design across discovery, pre-clinical and clinical studies. Through use of cutting-edge computational tools, bespoke models and our proprietary Virtual Tumour technology, the Physiomics team has informed the development of over 100 commercial projects, with over 125 targets and drugs modelled. Clients include Merck KGaA, Astellas, Bicycle Therapeutics, Numab Therapeutics & CRUK.